MOTS-c + SS-31: Mitochondrial Optimization
A mitochondrial-targeted combination pairing two peptides with distinct but complementary mechanisms. MOTS-c enhances glucose metabolism and AMPK signaling while SS-31 (Elamipretide) stabilizes cardiolipin in the inner mitochondrial membrane, protecting against oxidative damage. Researched in contexts of aging, metabolic dysfunction, and exercise performance.
Safety Notes
MOTS-c is a mitochondria-derived peptide studied primarily in preclinical models; human clinical data is very limited. SS-31 (elamipretide) is an investigational drug currently in Phase 2/3 clinical trials for Barth syndrome and heart failure — it is not approved for any indication. Neither compound is approved for general health or anti-aging use. Long-term safety profiles for both are still being established through ongoing clinical research.
Peptides in This Stack
- 1MOTS-cLongevity
Mitochondria-derived signaling peptide that activates AMPK and enhances glucose uptake. Multiple studies demonstrate improved exercise capacity and metabolic health in aged models.
- 2SS-31Longevity
Targets cardiolipin in the inner mitochondrial membrane, reducing ROS production at the source. Phase 2/3 trials for mitochondrial myopathy and heart failure.
Research References
Established
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistanceCell Metab 2015 · PMID 25738459
- First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergeticsBr J Pharmacol 2014 · PMID 23991888
- Coordinated deficiency of complex I subunits in aging contextJ Gerontol A Biol Sci Med Sci 2020 · PMID 31588495
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.